United States

Ocular Therapeutix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration ...

Lead Product(s): Dexamethasone

Therapeutic Area: Ophthalmology Product Name: Dextenza

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 23, 2020

Details:

First Coast Service Options became the second MAC to establish a physician fee schedule for procedure code 0356T for the administration of drug-eluting intracanalicular inserts, including DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg, effective July 1, 2020.

Ocular Therapeutix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)

Lead Product(s): Dexamethasone

Therapeutic Area: Ophthalmology Product Name: Dextenza

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2020

Details:

Despite the ongoing market challenges amid COVID, the Company had its strongest month to date in DEXTENZA in-market sales in June as Ambulatory Surgery Centers (ASCs) and hospital outpatient departments purchased 2,294 billable inserts.

Osmotica Pharmaceutical Corp.

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in Adults

Lead Product(s): Oxymetazoline

Therapeutic Area: Ophthalmology Product Name: Upneeq

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 09, 2020

Details:

U.S FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can limit field of vision.

Sonoma Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe for its Microdacyn60® Eye Care

Lead Product(s): Hypochlorous Acid

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Brill International S.L

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 26, 2020

Details:

Sonoma has agreed on a 10-year license, distribution and supply agreement with its distribution partner Brill International S.L. to market the eye care product under the private label Ocudox™ in the European markets of Italy, Germany, Spain, Portugal and the United Kingdom.

Aerie Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19

Lead Product(s): Netarsudil Mesylate

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2020

Details:

Aerie expects to hold a meeting with the regulatory authorities in Japan during to discuss Phase 3 trial designs for Rhopressa® while continuing to explore partnership opportunities.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Ocular Therapeutix

Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration ...

Ocular Therapeutix

Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)

Osmotica Pharmaceutical Corp.

Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq for Acquired Blepharoptosis (Droopy Eyelid) in Adults

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe for its Microdacyn60® Eye Care

Aerie Pharmaceuticals

Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19